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ABSTRACT
Introduction: Increased knowledge of breast cancer risk factors may enable a paradigm shift from the
current age-based mammographic screening programmes to a personalised risk-based approach. This
would warrant a significant change in practice, yet the acceptability from a woman’s perspective has
never been systematically explored. In this systematic review, we inventoried and appraised studies of
women’s perceptions of risk-based breast cancer screening and prevention to identify factors associ-
ated with adopting this new paradigm.
Methods: We searched Medline, Embase and PsycInfo to identify original articles in English containing
perceptions of risk-based breast cancer screening and/or primary prevention of women with an aver-
age to above average risk of developing breast cancer. Qualitative data were systematically extracted
and referenced against four theoretical models of preventative health behaviour adoption.
Results: When considering the adoption of this novel screening and prevention programme, women
carefully review their perceived susceptibility to breast cancer. Their decisions are based on a cost–be-
nefit analysis of adopting lifestyle changes, chemoprevention, or prophylactic surgery, taking into
account their perceived competence, individual autonomy, relatedness to others, and personal prefer-
ence. The role of intent is limited when considering behavioural change.
Conclusions: Implementing risk-based breast cancer screening and prevention will require a multifac-
torial approach. The transition from theory to practice can be supported by developing evidence-based
shared decision aids and family-oriented (genetic) counselling programmes.
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Introduction
Increased knowledge of breast cancer risk factors may enable
us to move from current ‘one-size-fits-all’ population-based
breast cancer screening programmes to a more personalised
risk-based approach. A woman’s screening strategy could be
optimised by integrating individual variations in breast can-
cer risk [1]. The efficiency of risk-based breast cancer screen-
ing has been modelled showing increased detection of
breast cancers in younger women at higher risk, a potential
reduction in false-positive outcomes and overdiagnosis, and
improved cost-effectiveness [2]. Hence, this approach could
improve the balance between the benefits and harms of
screening for women with either a lower or higher than aver-
age risk of developing breast cancer [2]. Classifying women
according to breast cancer risk at a population level will also
provide greater opportunities for primary prevention. Women
can attempt to actively reduce their breast cancer risk by
participating in a lifestyle programme or taking risk-reducing
medication (chemoprevention). Risk-based breast cancer
screening and prevention would require extensive changes
to current practice and women’s participation is a prerequis-
ite for potential cost-effectiveness and successful implemen-
tation [3]. Yet, the acceptability of risk-based breast cancer
screening and primary prevention has never been systematic-
ally explored from the perspective of eligible women.
Currently, prevention strategies, such as risk-reducing
medication, are only discussed with women at high risk of
developing breast cancer (i.e., 10-year risk8%) [4]. However,
the National Institute of Health and Care Excellence (NICE)
guidance states that risk-reducing medication should also be
mentioned to women with a moderate risk of breast cancer
(i.e., 10-year risk of 5–8%) [4]. In addition, all women, regard-
less of breast cancer risk, may benefit from information on
healthy lifestyle behaviours, especially as behaviours like a
high calorie intake diet and lack of exercise are also impli-
cated in other medical conditions [5].
The introduction of personalised risk-based screening and
subsequent primary prevention would require women to
make substantial changes to their current screening and pre-
ventative health behaviours. Exploring factors that may
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influence women’s adoption of the novel programme will
provide valuable insights for future implementation.
Therefore, the objective of the present study is to systematic-
ally explore and appraise studies of women’s perceptions of
integrated risk-based breast cancer screening and prevention.
Based on this analysis, we will develop a conceptual frame-
work illustrating the factors that potentially influence wom-
en’s acceptability of this new screening and prevention
programme for breast cancer.
Methods
Search strategies
We used two search strategies to identify articles on wom-
en’s perceptions of the adoption of personalised risk-based
breast cancer screening and prevention. The construct
‘perceptions’ was operationalised to include ‘attitudes’ and
‘perspectives’ to achieve a broad overview of women’s reac-
tions to the new screening strategy. Medline (1966–January
2016), EMbase (1974–January 2016) and PsycINFO
(1806–January 2016) were searched to obtain a comprehen-
sive result. The complete search strategies are available in
Supplement 1. Reference lists of relevant reviews and the
included articles were screened to identify additional studies.
Selection criteria
An article was selected for inclusion when it concerned a full-
text original article in English (i.e., not a review), aiming to
evaluate perceptions of personalised risk-based breast cancer
screening (of women with an average risk of developing breast
cancer) and/or primary prevention (of women with an average
to above average risk of developing breast cancer). This distinc-
tion was made because women who attend screening are con-
sidered to have a population-average risk of developing breast
cancer, whereas prevention is generally aimed at women who
have an increased risk of developing breast cancer. Exclusion
criteria were: study population of BRCA1/2 carriers or women
who had previously been diagnosed with breast cancer, per-
spectives of (healthcare) professionals, perceptions of current
population-based screening programmes, and articles which
solely evaluated the effectiveness of an intervention (not con-
sidering women’s perceptions). Two researchers independently
screened each title, abstract, and full-text article (LR, DvdW, AJ,
YW, MB). One researcher appraised the methodological quality
of the included studies (LR). When disparities arose, consensus
was reached through discussion.
Methodological quality assessment
Studies were appraised using the Critical Appraisal Skills
Programme (CASP) tool from the National Health Service
Public Health Resource unit [6]. This tool allows a systematic
inventory of the quality and validity of studies, is easily
accessible, and is commonly used in systematic reviews.
Subsequently, relevant data were collected using a data
extraction form containing information on the study
population, recruitment methods, design, main outcomes,
and generalisability. The Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guideline
was used to guide the reporting of this systematic review [7].
Synthesis of results
Although we intended to perform a quantitative meta-analysis,
the included studies did not meet the established require-
ments [8]. Since ‘acceptability’ is a relatively broad term, it was
defined and measured differently in the included studies, pre-
venting meaningful insights from averaging the results. To
summarise the quantitative research, the key quantitative find-
ings are presented systematically (Supplement 2). In this
review, we focus on the qualitative results regarding the main
outcome defined as women’s perceptions of risk-based screen-
ing and preventative behaviour adoption.
The qualitative data were systematically extracted from
each study and analysed without any preconceived theories
in mind using Braun and Clarke’s method, i.e., familiarisation
with the data, organising data into meaningful groups using
a data-driven strategy, developing themes by evaluating
overarching topics and relationships, and studying the inter-
connectedness of the topics [9]. This leads to the identifica-
tion of meaningful qualitative statements and themes. These
extracted statements and themes were subsequently linked
to four known theoretical models which aim to explain
breast cancer health behaviour adoption, i.e., motivation
interviewing (MI), the health belief model (HBM), self-determin-
ation theory (SDT) and the preventive health model (PHM) [10].
Table 1 provides an overview of the four theoretical models.
In the analysis, we distinguished between women’s percep-
tions of risk-based screening, lifestyle changes, chemopreven-
tion, and prophylactic surgery.
Results
Characteristics of included studies
The search strategy for women’s perceptions of risk-based
breast cancer screening identified 1199 unique publications,
of which we selected 67 articles based on title and abstract.
Full-text screening resulted in the selection of four articles.
Reference checking identified two additional studies. In total,
six articles on risk-based screening were included (Figure 1).
The search strategy for women’s perceptions of breast cancer
prevention identified 4126 unique publications; 164 articles
were selected after title and abstract screening. Full-text
screening resulted in the selection of 38 articles. Reference
checking identified six additional eligible studies, leading to
a total of 50 studies on risk-based screening and prevention.
All included studies were appraised to be of average to good
quality [6]. Supplement 2 gives an overview of the general
characteristics and the key quantitative outcomes of the
included studies. Supplement 3 provides detailed qualitative
information of women’s perceptions of risk-based breast can-
cer screening and prevention. Lastly, Supplement 4 provides
an overview of the extent to which the four theoretical mod-
els were represented in the articles.
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Women’s perceptions of personalised risk-based screening
and prevention
Figure 2 shows the theoretical framework for risk-based
breast cancer screening and preventative health behaviour
adoption from the perspective of women. It illustrates how
women’s perceptions of this novel programme relate to the
four theoretical models of health behaviour adoption. The
HBM and SDT were applicable to women’s perceptions of
risk-based screening and all identified methods of preven-
tion, i.e., lifestyle (n¼ 28 studies), chemoprevention (n¼ 8),
and prophylactic surgery (n¼ 8). The theoretical model of MI
was only applicable to women’s perceptions of preventative
lifestyle changes. Women’s perceptions of all preventative
practices could be linked to PHM, although PHM was not
applicable to their perceptions of risk-based screening. We
describe women’s perceptions of risk-based breast cancer
screening and prevention in more detail below, relating it to
the four models and their key constructs (in italics).
Health belief model
Women reported favourable opinions about receiving risk
information to tailor breast cancer screening and prevention
[11–13]. Perceived susceptibility influenced perceptions of risk-
based screening and prevention, as higher perceived risk was
associated with a higher acceptance of increased screening
frequency, lifestyle changes, chemoprevention, and surgery
[14–26]. Low perceived risk, however, did not reduce
Figure 1. Flowchart of search strategy and article selection.
Table 1. Overview of the four theoretical models and the definitions of their underlying constructs.
Theoretical model Definition
Motivation interviewing [80]
Commitment to action Intent to adopt behavior
Health belief model [81]
Perceived susceptibility Perceived chance of getting the disease
Perceived severity Perceived seriousness of disease and subsequent consequences
Demographic factors Individual characteristics that can affect behavior, e.g., age, ethnicity, education
Psychosocial factors Individual characteristics that can affect behavior, e.g., personality, social class
Incentives Perceived value of a behavior in decreasing risk
Barriers Evaluation of obstacles preventing behavior adoption
Cues to action Strategies to activate behavior
Self-determination theory [82]
Autonomy Ability to act on own interests and values
Relatedness Interaction with and connection to others
Competence Ability to deal effectively with the environment
Preventive health model [83]
Preference clarification Ordering of alternatives based on relative utility
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perceived susceptibility, limiting the endorsement of a lower
screening frequency [12,14]. Additionally, perceived health
influenced women’s acceptability of chemoprevention, with
healthier women feeling less susceptible to breast cancer
and therefore less interested in chemoprevention [27,28].
Women’s perceived severity of breast cancer was affected by
having relatives who had been diagnosed with breast cancer
and by a more acute perception of other medical conditions,
e.g., diabetes or cardiovascular disease. The former made
women more likely to accept prophylactic surgery, the latter
made women less likely to accept chemoprevention
[21,27,29–32]. Several incentives for personalised risk-based
screening were identified, such as the feeling of empower-
ment through knowledge and the possibility to screen more
efficiently, reducing the screening burden for low risk women
[11,13]. Looking more attractive, reducing menopausal symp-
toms, and reducing the risk of other medical conditions were
identified as incentives for the adoption of lifestyle changes
[33,34]. The main incentive to chemoprevention acceptance
was comprehensive information on the effectiveness of che-
moprevention [17,27,35]. Surgical options after mastectomy,
e.g., breast augmentation were incentives to opt for prophy-
lactic surgery [24,29,36]. Barriers to risk-based screening
included the need for family risk communication, a lack of
insurance coverage, and possible employer/insurance discrim-
ination [11–13,37]. Barriers to the acceptance of lifestyle
changes were costs, time investment, and the lack of a clear
message on how lifestyle affects breast cancer risk [15,33]. A
main barrier to chemoprevention was the perception of
potential side effects, with women consistently overestimat-
ing the risk of developing complications after chemopreven-
tion use [18,19,27,28,31,32,38–46]. Main barriers to
prophylactic surgery included not having health insurance or
financial stability, the perceived radical nature of the proced-
ure, and relying on prayer and spirituality [24,47]. Feeling
happier and overcoming depression were psychosocial factors
associated with higher acceptance of healthy lifestyle
changes [33]. Increased cancer worry, anxiety and intrusive
thinking were associated with higher interest in chemopre-
vention and prophylactic surgery (psychosocial) [18,19,21,22,
24,30,48–50]. However, the perception that losing your
breasts would affect body image and identity limited accept-
ance of prophylactic surgery (psychosocial) [24,29,51].
Self-determination theory
Women reported feeling insecure about the potential impact
personal risk information could have on their lives and their
ability to manage any potential consequences (competence)
[11]. A perceived lack of knowledge limited acceptance of
risk-based screening and all preventative methods
[20,36,44,47,51]. Lacking faith in own ability (competence) hin-
dered participation in a lifestyle programme specifically
[33,47]. Moreover, women indicated that having to decide on
chemoprevention was a great responsibility (competence),
worrying about disrupting their current state of health
[28,32,38]. The term ‘chemoprevention’ elicited especially
strong reactions from women [17,31]. Perceiving control over
and accepting responsibility for own health (autonomy) were
motivators for adopting preventative behaviours [17,32,39].
Additionally, the importance of social support from friends
and family (relatedness) was emphasised in the decision-mak-
ing process for risk-based screening and prevention in gen-
eral [20,30,31,33,36,38,44,47,50,52–54].
Motivation interviewing
Women generally accepted lifestyle changes for reducing
breast cancer risk, however, they were concerned that they
lacked the willpower to affect change (commitment to action)
[15,33,47,55]. One study confirmed this, showing high intent
Figure 2. Proposed framework of the acceptability of risk-based breast cancer screening and preventative health behavior adoption, from a woman’s perspective.
HBM¼ health belief model; SDT¼ self-determination theory; PHM¼ preventive health model; MI¼motivational interviewing.
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but low behavioural change (e.g., diet and exercise) after
breast cancer risk communication [33].
Preventive health model
Several studies compared women’s perceptions of chemopre-
vention and prophylactic surgery. Although women generally
preferred chemoprevention to surgery, they required a guar-
anteed risk reduction of 50–100% to conceive of either pro-
cedure as acceptable preventative options (preference
clarification) [17,50,56,57]. Moreover, increased surveillance
was preferred to prophylactic surgery (preference clarifica-
tion) [30,50].
Women’s communication and information needs regard-
ing personalised risk-based screening and prevention
Women identified the screening organisation as being the
most suitable setting to perform a risk assessment, prior to
mammography screening [11]. However, women were div-
ided about their preferred way of being informed about their
risk of breast cancer. Some preferred a consultation, a tele-
phone call, or an e-mail, either from a cancer specialist or a
GP [12]. Women who were offered the option of receiving
personalised breast cancer risk information on a secure web-
site responded positively [58]. Additionally, women would
welcome supplementary printed materials, interactive group
education sessions, and support groups to help them cope
with personal risk information [58].
The primary care physician was identified as the most
important source of information on chemoprevention [42].
Women’s information needs included the reliability and
effectiveness of medication, and decision-making guidance
[40,59]. Women prefer the physician to assume a directive
role, taking a woman’s personal preference into account [40].
Women have difficulty differentiating between a physician
lacking knowledge and knowledge not being available [60].
Physicians expressing uncertainty can either be perceived as
anxiety inducing or as truthful [60]. Women suggested sev-
eral options for improving physician–patient communication,
e.g., additional training to educate physicians on the import-
ance of shared informed decision-making, getting a second
opinion, developing culturally appropriate intervention proj-
ects, and creating an open environment where both appreci-
ation and grievances can be expressed [42]. Most women felt
that some form of counselling or a support group was
needed after risk communication, because they felt isolated
[30,40]. Communicating decisions on prevention to family
members was perceived as difficult, with women experienc-
ing relatives’ fear, shock and bereavement [29,30,51].
Discussion
This review provides a framework for the factors that may
influence women’s participation in personalised risk-based
breast cancer screening and prevention (Figure 2). Decision-
making about the adoption of this programme appears best
described by a cognitions-based process, whereby women
evaluate the perceived threat of breast cancer and consider
the pros and cons of available preventative strategies in their
social context. The limited role of intent is unsurprising and
in line with previous research, which shows that interven-
tions relying solely on intent had limited effects on health
behaviour change [61]. Seeking behaviour change through
intent is particularly challenging for those women who per-
ceive a low sense of control over their own health [62].
Moreover, breast cancer prevention requires relatively
ambiguous and long-term efforts.
Adopting risk-based screening
Women appear in favour of receiving personalised informa-
tion on breast cancer risk, with all studies showing a gener-
ally positive attitude. Women’s general interest in breast
cancer risk information has previously been demonstrated
[63]. Evans and colleagues recruited women from the United
Kingdom National Health Service breast screening pro-
gramme and found that 95% of their study participants
wanted to know their personal breast cancer risk.
Additionally, receiving risk information had no adverse effect
on screening attendance for high risk women who were
more likely to attend their subsequent mammogram [64].
Our review showed that incentives for women’s uptake of a
risk-based screening programme include increased know-
ledge, a sense of empowerment, and the inclusion of lifestyle
factors to increase perceived control over breast cancer risk.
This confirms that receiving exclusively genetic risk informa-
tion limits women’s motivation and hinders potential behav-
ioural change [65]. The prominent role of perceived control
in health behaviour adoption has previously been demon-
strated in a review of women carrying a BRCA mutation [66].
Adopting lifestyle changes
Overall, women appeared to welcome the opportunity to
modify their personal risk through diet and exercise with four
of the seven studies on lifestyle changes reflecting an accept-
ing attitude. Women’s apparent acceptance is a potentially
important finding, as it is feasible that the Western lifestyle –
characterised by dietary and reproductive changes, and
increased sedentary activity – has contributed to the world-
wide increase of breast cancer cases [63]. Adopting a healthy
lifestyle, in particular sustained postmenopausal weight reduc-
tion, could lead to a breast cancer risk reduction of around
25% [67]. However, a woman’s intention to improve lifestyle
does not guarantee behavioural change [60,68]. In this review,
we show that women reported a general lack of commitment
to lifestyle changes because they believe they lack the will-
power. A prominent factor hindering the uptake of lifestyle
changes was the absence of a clear message on the relation
between lifestyle and breast cancer risk. Primary care facilities
or screening providers could be opportune places to increase
women’s knowledge by providing group education sessions
collectively endorsing national guidelines on cancer prevention
lifestyle practices [69]. This could improve general feelings of
competence and autonomy, as well as improving the
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perceived cost–benefit balance of adopting healthy risk-reduc-
ing lifestyle behaviours.
Adopting prophylactic surgery and
chemoprevention
The consideration of prophylactic surgery and chemopreven-
tion in the general population was contingent on a (very)
high perceived breast cancer risk (75–100%). The fact that
prophylactic surgery lacks general acceptance is unremark-
able, as this procedure was discussed with women who do
not meet the risk requirements. Women eligible for prophy-
lactic surgery are usually identified as high risk prior to
screening and are therefore generally already under surveil-
lance at a hospital or a health clinic [4].
Women’s apparent limited acceptance of chemopreven-
tion is more relevant, because more women are expected to
meet the eligibility criteria after breast cancer risk assess-
ment. Studies performed at screening centres and general
practices identified an additional 3% of women meeting the
Tyrer–Cuzick cut-off criterion for moderate risk and thus che-
moprevention [63,70,71]. These women would previously
have gone undetected by only inventorying family history.
Clinical trials have demonstrated breast cancer risk reductions
of 35–40% [71]. The general uptake of and adherence to che-
moprevention is low, despite its proven effectiveness in
clinical trials and its endorsement by the Food and Drug
Administration, the American Society for Clinical Oncology
and the National Comprehensive Cancer Network [72].
Acceptance of chemoprevention in our study appears to be
mainly hindered by the severity of the perceived side effects.
Beneficial effects of lower tamoxifen doses on breast cancer
incidence have been observed [73]. Therefore, determining
the minimal effective dose could improve uptake.
Additionally, two studies reported a general aversion to the
name chemoprevention, as it elicited painful memories and
associations with chemotherapy. Several alternative names
have been suggested, e.g., preventative therapy or risk-reduc-
ing medication [74]. These names may elicit milder
responses, leaving more room for deliberation.
Risk communication
Women consistently identified the opinion of the physician
as a motivator to adopt risk-based screening and prevention.
This demonstrates the importance of optimal communication
with care-providers. The significant challenges associated
with health communication in general and risk communica-
tion in particular have previously been evaluated in a com-
prehensive review [75]. This review showed that women who
were presented with a personal breast cancer risk often mis-
understood the (long-term) implications of their risk.
Understanding risk information is a vital step in the adoption
of tailored preventative behaviours. Previous recommenda-
tions for improving the quality of risk communication in
practice are in line with the information needs of women
identified in our review, e.g., preference for printed materials
and web-based risk communication formats [76]. This
highlights the relevance of developing evidence-based,
shared decision-making protocols to enable women to
increase their perceived autonomy, competence and sense of
relatedness, aiding potential preventative health behav-
iour adoption.
In addition, women emphasised their relatedness to sig-
nificant others, e.g., friends, relatives, partner and children. To
date, risk-related communication in the family setting has
received little attention, but this is an essential part of this
new screening and prevention programme. This review
shows that women feel socially isolated, are concerned for
family members’ reactions, fearful of judgement, and worried
about reiterating past bereavement regarding relatives’
missed prevention opportunities, breast cancer diagnosis,
and breast cancer related deaths. These family-oriented
themes were also identified in a study among women who
were at high risk of carrying a BRCA mutation [77].
Discussions with potential BRCA carriers established five fam-
ily-related themes, i.e., distress about possible transmission to
children, family conflict about testing, concerns about dis-
closure, different coping styles and decision-making, and
underlying family conflict and unresolved grief [77]. This
highlights the need to counsel women on how to communi-
cate risk information and subsequent preventative choices to
family members to aid potential health behaviour adoption.
Strengths and limitations
To our knowledge, this review proposes the first framework
of women’s perceptions of a novel risk-based breast cancer
screening and subsequent prevention programme. Although
effects of breast cancer risk feedback, general decision-mak-
ing, and uptake of prevention have previously been studied
[75,78], there is a lack of information on women’s motiva-
tions behind potential adoption or rejection of the integrated
early detection and prevention programme. However, our
proposed framework has one main limitation, namely that
women’s perceptions of risk-based screening and prevention
were generally explored outside of the infrastructure of a
population-based screening programme. Unfortunately, stud-
ies in which this new screening and prevention paradigm is
already embedded in current practice are rare, yet this is piv-
otal for future implementation.
The comprehensive and systematic nature of the literature
search allowed for an extensive overview of women’s percep-
tions of personalised risk-based screening and primary pre-
vention for breast cancer. Although the search identified
both quantitative and qualitative study results, a meta-ana-
lysis of quantitative data was not attainable, due to the het-
erogeneity in the measurement of study determinants and
outcomes. To increase the comparability of future studies,
consensus is required on the aspects which define accept-
ability of personalised screening and primary prevention
from a woman’s perspective. Our conceptual framework may
offer guidance in this.
The studies on biomedical prevention, in particular those
on chemoprevention, were mostly performed in the United
States (US). Since the US does not have a population-based
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screening programme and the provision of prevention is
more individualised, it is unclear whether these results are
generalisable to a population-based screening setting. A
review of studies with BRCA1 and BRCA2 mutation carriers
has shown significant international variations in the rates of
chemoprevention uptake, with higher rates in the US com-
pared to, e.g., Europe [79]. Future research is required to
explore women’s perceptions of biomedical prevention in a
breast cancer screening setting.
Conclusions
This review provides a conceptual framework which illus-
trates the factors that influence women’s acceptability of the
adoption of personalised risk-based breast cancer screening
and prevention. Women’s adoption appears to be based on a
careful consideration of perceived susceptibility to breast
cancer and a cost–benefit analysis of the potential health
behaviours, taking into account perceived competence,
autonomy, relatedness, and personal preference. To meet
women’s needs in this decision-making process, significant
changes in current practice are required. Developing evi-
dence-based shared decision aids and family-oriented (gen-
etic) counselling programmes will aid the transition from
theory to practice.
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